Early pirfenidone treatment enhances lung function in idiopathic pulmonary fibrosis patients

doi:10.12998/wjcc.v12.i28.6247

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 28

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (815)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

623

Sum=650

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

102

Sum=133

Oct 6, 2024 (publication date) through Dec 25, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Clin Cases. Oct 6, 2024; 12(28): 6247-6249
Published online Oct 6, 2024. doi: 10.12998/wjcc.v12.i28.6247

Early pirfenidone treatment enhances lung function in idiopathic pulmonary fibrosis patients

Jin-Wei Zhang

Jin-Wei Zhang, Medical School, University of Exeter, Exeter EX4 4PS, United Kingdom

Author contributions: Zhang JW designed the overall concept and outline of the manuscript; Zhang JW contributed to the discussion and design of the manuscript; Zhang JW contributed to the writing and editing of the manuscript, illustrations, and review of the literature.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Jin-Wei Zhang, BSc, MSc, PhD, Academic Editor, Professor, Senior Editor, Medical School, University of Exeter, Stocker Rd, Exeter EX4 4PS, United Kingdom. j.zhang5@exeter.ac.uk

Received: June 29, 2024
Revised: July 25, 2024
Accepted: July 30, 2024
Published online: October 6, 2024
Processing time: 44 Days and 23.5 Hours

Core Tip

Core Tip: Early intervention with pirfenidone in idiopathic pulmonary fibrosis (IPF) patients significantly improves lung function, reduces inflammation, enhances physical endurance, and decreases adverse reactions. These findings underscore the potential of early pirfenidone treatment to alter the disease course and improve patient outcomes, emphasizing its importance in clinical management strategies for IPF.